
Tenon Medical (NASDAQ:TNON) reported third-quarter revenue of $1.4 million, up 22% from a year earlier, as more physicians used its sacroiliac joint fusion systems. The company’s net loss widened, however, partly because of noncash charges associated with warrants and convertible debt.
Revenue also rose 12% from the second quarter. President and CEO Steve Foster said Tenon completed more procedures with more physician users than in either comparison period, driven by adoption of its Catamaran and SImmetry platforms.
The company completed 36 combined physician and distributor training activities during the quarter, which Foster described as a leading indicator of adoption.
Margins improve as operating loss narrows
Third-quarter gross profit rose 23% to $1 million, while gross margin increased to 66.3% from 65.9% a year earlier. CFO Kevin Williamson attributed the improvement to higher revenue absorbing more fixed costs and lower per-procedure costs for Catamaran following a July regulatory clearance that reclassified certain instruments as reusable.
Operating expenses fell to $4 million from $4.2 million, primarily because of lower professional service fees. Higher sales and marketing costs and increased research and development spending partly offset that decrease, Williamson said. The operating loss narrowed to $3.1 million from $3.4 million.
Net loss widened to $6.6 million, or $5.39 per share, from $3.3 million, or $14.17 per share, a year earlier. Williamson said the increase primarily reflected noncash items below the operating line, including $3.1 million of expense related to warrants issued in a September warrant inducement transaction and $0.7 million of noncash interest expense tied to the amortization of debt discount on convertible notes.
All per-share figures reflect Tenon’s 1-for-35 reverse stock split on Aug. 10, 2026, Williamson said.
For the first nine months of 2026, revenue increased 66% to $4.1 million, while gross margin rose to 66.2% from 54.4%. The nine-month operating loss narrowed to $9.7 million from $9.9 million, although the net loss widened to $14.2 million from $9.7 million.
Product launches and sales expansion
Tenon announced the full commercial launch of a titanium 3D-printed lateral screw for its SImmetry+ SI joint fusion system on Sept. 30. Foster said a preceding limited launch generated approximately $1.2 million in revenue from late in the fourth quarter of 2025 through the third quarter of 2026.
The screw is the first component of Tenon’s next-generation lateral SI joint fusion system, Foster said. He described the Catamaran and SImmetry+ platforms as complementary tools that offer different approaches to the same anatomy.
After the quarter ended, Tenon announced completion of initial alpha cases for its Quickstep Decorticator, designed to simplify the SImmetry+ surgical workflow. The company is targeting a full market release in the first quarter of 2027 and anticipates an early December 2026 submission for an enhancement to the SImmetry+ implant.
Foster said Thomas Batton Jr. joined Tenon as chief revenue officer effective Oct. 1. The company plans to add direct sales representatives and independent distributor partners under his leadership.
Debt repaid and cash position strengthened
Tenon ended September with $8.3 million in cash and cash equivalents, up from $3.8 million at the end of 2025. It raised approximately $15.6 million in aggregate gross proceeds through multiple transactions during the quarter.
The company also repaid its senior convertible notes, which had approximately $5.16 million in aggregate principal, ahead of their Sept. 11 maturity. Williamson said Tenon had no outstanding debt at quarter-end. Foster said the company regained compliance with Nasdaq’s stockholder equity and minimum bid price requirements.
After quarter-end, Tenon increased availability under its at-the-market offering program to approximately $7.1 million, which Williamson said the company expects to support future capital needs.
About Tenon Medical (NASDAQ:TNON)
Tenon Medical, Inc. (NASDAQ:TNON) is a medical device company focused on developing and commercializing technologies for the treatment of sacroiliac (SI) joint dysfunction. The SI joint connects the lower spine to the pelvis and can be a source of chronic lower-back and pelvic pain. The company’s primary product is the Catamaran SIJ Fusion System, a minimally invasive surgical system designed to stabilize and fuse the SI joint through a transfixation approach. The system uses a specialized implant and delivery instruments intended to support placement across the SI joint while addressing the underlying source of instability.
